Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
TherapeuticsMD reported net income of $0.49 million for the quarter ended September 30, 2026, compared to $0.15 million in the prior year period, driven by increased license revenue from its royalty-based business model. The company maintained a stable balance sheet with $10.4 million in cash and total stockholders' equity of $27.6 million.
IEH Corporation reported record financial results for its second fiscal quarter ended September 30, 2026, with revenue increasing 51% year-over-year to $10.7 million. The company achieved a record backlog exceeding $56 million and returned to profitability with net income of $1.36 million compared to a net loss in the prior year period.
Term
Q2 2027
“As great as this year’s first quarter was, the second quarter exceeded it by every measure. The first quarter’s record revenue of $10 million was eclipsed by this quarter’s $10.7 million. Similarly, our operating profit increased 57%, and our net income and earnings per share both more than doubled.”
Dave Offerman, President and CEO of IEH Corporation
“We shattered our previous backlog record by 40%, and we continue to hire and add capacity and equipment to meet the surge in demand in the defense, commercial aerospace, space and medical markets we serve.”
Dave Offerman, President and CEO of IEH Corporation
Incyte Corporation has decided not to proceed with its planned Phase 3 MAESTRA-3 study of INCB123667 in combination with bevacizumab for ovarian cancer. The decision was based on internal portfolio prioritization rather than safety or efficacy concerns and is not expected to impact the company's financial guidance.
Silvaco Group Insider Candace Jackson Sells $22.4K of Stock
Candace Jackson sold 3,000 shares of Silvaco Group, Inc. at $7.45 a share, worth $22.4K in total on Nov 12, 2026. Shares held after the trade: 41,722 (-6.7%).
Seneca Bancorp, Inc. reported a net income of $129,000 for the nine months ended September 30, 2026, compared to $137,000 in the prior year period. While net interest income increased significantly to $7.7 million, the results were impacted by higher noninterest expenses, including a $262,000 impairment of long-lived assets and increased compensation costs.
Boston Omaha Corporation reported total revenues of $22.2 million for the third quarter of 2026, a slight increase from $21.9 million in the prior year. The company recorded a net loss attributable to common stockholders of $0.2 million for the quarter, an improvement from a $2.6 million loss in Q3 2025, primarily driven by equity in income of unconsolidated affiliates and income from discontinued operations.
Prospect Floating Rate & Alternative Income Fund, Inc. reported total investment income of $2.05 million for the quarter ended September 30, 2026, a slight decrease from $2.19 million in the prior year period. Net assets increased to $38.01 million from $37.10 million at fiscal year-end, while the net asset value per share for Class A and Class I shares decreased slightly to $3.88.
Curis, Inc. reported a total stockholders' equity of $2.55 million as of September 30, 2026, a decrease from $5.46 million at the end of 2025. The company continues to incur substantial losses, with an accumulated deficit reaching $1.29 billion, and management has identified conditions that raise substantial doubt about its ability to continue as a going concern.
Lisata Therapeutics reported a significant increase in total assets to $648.4 million following the acquisition of Marea, which added $292.9 million in intangible assets and $64.7 million in goodwill. The company recorded a net loss of $6.8 million for the third quarter of 2026, with research and development expenses increasing to $5.2 million as they advance their combined pipeline.
Science Applications International $500M Debt Financing with Truist Bank
Science Applications International Corporation (SAIC) closed a private offering of $500 million in 6.750% Senior Notes due 2034. The company used the net proceeds of approximately $493 million to redeem its outstanding 4.875% Senior Notes due 2028 and for general corporate purposes.
For the three months ended September 30, 2026, OptimizeRx reported net revenue of $21.6 million and net income of $1.2 million, compared to $26.1 million and $0.8 million in the prior year period. While quarterly profitability improved, the company recorded a slight net loss of $3,000 for the nine-month period as revenues declined from $77.2 million to $62.0 million year-over-year.
Vistagen reported financial results for its fiscal year 2027 second quarter ended September 30, 2026, and provided a corporate update on its fasedienol Phase 3 development plan for social anxiety disorder. The company highlighted constructive FDA feedback regarding its clinical trial design and the appointment of Dr. Douglas J. Williamson to its Board of Directors. Vistagen also implemented cost-management initiatives to prioritize capital for its late-stage neuroscience programs.
Term
Q2 2027
“Following our recent productive meeting with the FDA and our evaluation of the extensive body of efficacy, safety, and patient experience data generated throughout Phase 2 and Phase 3 development of fasedienol, we believe we have clarity on the potential regulatory pathways forward for fasedienol in social anxiety disorder”
Shawn Singh, President and Chief Executive Officer of Vistagen
“Recent alignment of our operating structure and capital resources with our late-stage development opportunities in both social anxiety disorder and menopausal hot flashes, position us to execute our plan to advance these programs while maintaining flexibility to create long-term shareholder value.”
Shawn Singh, President and Chief Executive Officer of Vistagen
Werewolf Therapeutics is currently pursuing a merger with Ambros and a concurrent PIPE financing to address substantial doubt about its ability to continue as a going concern. As of November 9, 2026, the company had 48,599,066 shares of common stock outstanding and is evaluating strategies to raise additional capital to fund its research and development programs.
Inhibrx Biosciences reported Q3 2026 financial results, highlighting a cash position of $199.5 million and $2.0 million in revenue from a licensing agreement with Pfizer. The company is advancing its clinical pipeline, with upcoming data presentations for ozekibart in Ewing sarcoma and ongoing enrollment in the Phase 2 HexAgon study for ordastobart.
Republic Digital Acquisition Company is a special purpose acquisition company (SPAC) that reported 30,000,000 Class A and 7,500,000 Class B ordinary shares outstanding as of November 13, 2026. The company's cash position decreased from $1,016,713 at the end of 2025 to $643,377 as of September 30, 2026, as it continues to seek an initial business combination within its designated 24-month period.
For the nine months ended September 30, 2026, Royalty Management Holding Corp reported total revenue of $5.63 million, a significant increase from $3.55 million in the prior year, primarily driven by environmental services. Despite the revenue growth, the company realized a net loss of $257,687 for the period, though this was an improvement over the $317,131 net loss reported in the same period of 2025.
Adaptin Bio, Inc. reported a net loss of $3.31 million for the nine months ended September 30, 2026, compared to a $3.80 million loss in the prior year period. The company remains in the development stage with no revenue, maintaining a stockholders' deficit of $1.67 million and a cash balance of $430,333 as of the reporting date.
Digimarc reported a total revenue of $6.4 million for the third quarter of 2026, a decrease from $7.6 million in the prior year, primarily driven by lower subscription revenue. The company's net loss narrowed slightly to $7.9 million for the quarter, while cash and cash equivalents increased to $20.7 million as of September 30, 2026.
EnerSyn Global Inc. reported a significant increase in total assets to $17.8 million as of September 30, 2026, driven by a substantial cash infusion and common stock issuances. However, the company experienced a widened net loss of $3.4 million for the nine months ended September 30, 2026, primarily due to a sharp rise in general and administrative expenses.
Rocket One Inc. reported a total asset increase to $8.66 million as of September 30, 2026, driven by new intangible assets and goodwill, despite a decrease in cash and cash equivalents. The company's accumulated deficit grew to $82.09 million, reflecting ongoing operational losses during its strategic repositioning into orbital and defense technologies.
KDT Ibotta Holdings LLC, 10% Owner, sold 274,999 shares of Ibotta, Inc. at $58.97 to $59.97 a share (average $59.55) in 4 transactions, worth $16.4M in total between Nov 11, 2026 and Nov 12, 2026. Shares held after the trade: 3,014,129 (-3.2%).
MEDO Technologies, Inc. reported a net loss of $191,301 for the three months ended September 30, 2026, and a cumulative net loss of $400,884 for the nine-month period. The company remains in a deficit position with total stockholders' deficit of $395,563 and implemented a 1-for-100,000 reverse stock split effective September 23, 2026.
M. Farooq Kathwari has resigned as President and CEO of Ethan Allen, effective immediately. The Board has appointed Stefanie T. Ward as Interim CEO for a six-month term and expanded the Board of Directors with four new appointments, including Anna Brockway and Steve Oblak, to oversee a strategic reset of the company.
Hudson Pacific Properties President Mark T. Lammas Buys $43.6K of Stock
Mark T. Lammas, President, bought 5,000 shares of Hudson Pacific Properties, Inc. at $8.73 a share, worth $43.6K in total on Nov 12, 2026. Shares held after the trade: 25,225 (+24.7%).
BWX Technologies $500M Debt Financing with U.S. Bank Trust Company, National Association
BWX Technologies issued $500 million of 6.500% Senior Notes due 2034 in a private placement. The proceeds were used to fund a tender offer and consent solicitation to purchase and amend its existing 4.125% Senior Notes due 2028 and 2029, effectively refinancing its near-term debt.
Columbus Circle Capital Corp III is a shell company that completed its IPO on July 10, 2026, raising $230 million held in a trust account. As of September 30, 2026, the company has 23,665,000 Class A and 7,666,667 Class B ordinary shares outstanding and is seeking a business combination within a 24-month period.
SmartKem, Inc. reported a net loss of $24.1 million for the nine months ended September 30, 2026, significantly impacted by a $45.6 million loss on the write-off of bad debts and $11.9 million in ELOC commitment share expenses. Despite these losses, the company improved its balance sheet through debt-to-equity conversions and preferred stock issuances, ending the period with $4.3 million in cash and total stockholders' equity of $12.8 million.
Our Bond, Inc. reported a significant increase in net loss to $16.1 million for the nine months ended September 30, 2026, compared to $7.8 million in the prior year, driven by a doubling of operating expenses. Revenue slightly declined to $6.98 million, while the company maintained a stockholders' deficit of $16.97 million.
CERo Therapeutics Holdings, Inc. is an emerging growth company focused on developing its lead product candidate, CER-1236. As of November 13, 2026, the company reported 83,309,742 shares of common stock outstanding and noted the impact of its delisting from Nasdaq as a significant risk factor.
For the nine months ended September 30, 2026, CIFC Direct Lending Evergreen Fund reported total investment income of $22.8 million and net investment income of $10.3 million. Total net assets grew to $112.1 million, supported by $11.0 million in net increase from operations and $9.0 million in capital contributions, partially offset by $9.9 million in distributions and redemptions.